This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Lipids in Health and Disease Open Access 13 March 2022
-
Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects
Scientific Reports Open Access 19 November 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet https://doi.org/10.1016/S0140-6736(18)31785-9 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morris, A. Potential treatment strategy for NASH. Nat Rev Endocrinol 15, 129 (2019). https://doi.org/10.1038/s41574-019-0162-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0162-1
This article is cited by
-
Fat mass and obesity–associated protein promotes liver steatosis by targeting PPARα
Lipids in Health and Disease (2022)
-
Serum FGF21 levels are altered by various factors including lifestyle behaviors in male subjects
Scientific Reports (2021)